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Introduction: The appropriate application of genomic technologies in healthcare is sur-
rounded by many concerns. In particular, there is a lack of evidence on what constitutes 
an optimal genetic service delivery model, which depends on the type of genetic test 
and healthcare context considered. The present project aims to identify, classify, and 
evaluate delivery models for the provision of predictive genetic testing in Europe and in 
selected Anglophone extra-European countries (the USA, Canada, Australia, and New 
Zealand). It also sets out to survey the European public health community’s readiness to 
incorporate public health genomics into their practice.
Materials and equipment: The project consists of (i) a systematic review of published 
literature and selected country websites, (ii) structured interviews with health experts 
on the genetic service delivery models in their respective countries, and (iii) a survey 
of European Public Health Association (EUPHA) members’ knowledge and attitudes 
toward genomics applications in clinical practice. The inclusion criteria for the system-
atic review are that articles be published in the period 2000–2015; be in English or 
Italian; and be from European countries or from Canada, the USA, Australia, or New 
Zealand. Additional policy documents will be retrieved from represented countries’ 
government-affiliated websites. The results of the research will be disseminated through 
the EUPHA network, the Italian Network for Genomics in Public Health (GENISAP), and 
seminars and workshops.
Expected impact of the study on public health: The transfer of genomic technologies 
from research to clinical application is influenced not only by several factors inherent to 
research goals and delivery of healthcare but also by external and commercial interests 
that may cause the premature introduction of genetic tests in the public and private 
sectors. Furthermore, current genetic services are delivered without a standardized set 
of process and outcome measures, which makes the evaluation of healthcare services 
difficult. The present study will identify and classify delivery models and, subsequently, 
establish which are appropriate for the provision of predictive genetic testing in Europe 
2Unim et al. Delivery Models for Genetic Testing
Frontiers in Public Health | www.frontiersin.org August 2017 | Volume 5 | Article 223
INtroDUctIoN
The past decade has seen the emergence of Public Health 
Genomics (PHG)—a multidisciplinary field that has established 
scientific and policy foundations for the appropriate translation 
of genetic/genomics research into health benefits for individu-
als and populations (1). Still, many aspects of this nascent field 
need further investigation. This is particularly so as the rapid 
diffusion and extensive marketing of genetic tests for com-
mon diseases impact healthcare systems worldwide and raises 
questions on the proper provision of genetic services. A major 
concern regarding technology transfer in genetics is the prema-
ture introduction of genetic tests—i.e., the introduction of tests 
where the analytical and clinical validity, as well as the clinical 
utility, are not well documented. Although these issues are most 
concerning when considering predisposition testing, they may 
also apply to predictive testing. Another concern is the lack or 
insufficient evidence of cost-effectiveness of several genetic/
genomic applications already introduced in clinical practice 
(2, 3). Particularly, there is a lack of evidence on what constitutes 
an optimal genetic service delivery model. This optimal model 
depends on the type of condition targeted and the healthcare 
context considered.
In order to add to the evidence base, the present project, 
therefore, aims to identify genetic service delivery models for the 
provision of predictive genetic testing in the European context, 
and to classify, and evaluate them. The genetic service delivery 
models will be compared between European and extra-European 
(Anglophone) countries (Canada, USA, Australia, or New 
Zealand). The project also aims to assess knowledge and attitudes 
of European public health (PH) professionals regarding the deliv-
ery of genetic services, and to obtain a picture of European PH 
community’s readiness to incorporate PHG into their practice.
For the scope of this project, predictive genetic testing (also 
known as pre-symptomatic testing) is defined as the use of 
genetic testing to predict whether an individual will develop 
a genetic disease at a later stage of their life; this term is only 
applicable where the disease-associated mutation is known and 
highly penetrant (4).
The study will be carried out within the Personalized 
pREvention of Chronic DIseases (PRECeDI) project (Marie 
Sklodowska-Curie Research and Innovation Staff Exchange 
2014). The PRECeDI consortium is composed of five EU member 
countries (Italy, UK, Hungary, Spain, and the Netherlands) in 
collaboration with non-EU project partners (McGill University, 
Abbreviations: PHG, Public Health Genomics; EUPHA, European Public Health 
Association; NRG, National Reference Group; GENISAP, Italian Network for 
Genomics in Public Health; GSPP, USA Genetic Service Policy Project; PRECeDI, 
Personalized pREvention of Chronic DIseases.
Canada and Icahn School of Medicine at Mount Sinai, USA). 
The first task of the consortium was to obtain consensus among 
the project partners on the most suitable genetic tests that could 
be employed in the multicenter study. Four genetic tests have 
been selected during the preliminary meeting that took place 
in 2015 at Sapienza University of Rome (Italy). The selected 
genetic tests are for hereditary breast and ovarian cancer, 
Lynch syndrome, familial hypercholesterolemia (as examples 
of genetic tests of proven effectiveness and cost-effectiveness) 
(5), and familial thrombophilia (as an example of genetic test of 
unproven effect iveness and cost-effectiveness) (6, 7). The second 
task was to identify European countries that could participate in 
the multicentre study through consultation of researchers from 
the five-member countries of the PRECeDI consortium. The aim 
is to include as many countries as possible in order to obtain a 
more comprehensive picture of the provision of genetic testing 
and the implementation of genetic services delivery models in 
Europe.
There are a number of factors unique to each genetic service 
provision, which could be used to categorize genetic service deliv-
ery models. These factors have been summarized in 10 questions 
formulated by the USA Genetic Service Policy Project (GSPP) 
Report (8) (Figure 1) and include:
(i) practice setting and financial resources (public vs. private);
(ii) service provider and patient access [geneticists vs. primary 
care physicians/other medical specialists (e.g., cardiologists, 
oncologists, neurologists, endocrinologists, and so on)];
(iii) policy regulation (national and local policies, guidelines, 
protocols, and position statements);
(iv) laboratory practice standards (quality control standards, 
qualified personnel, etc.);
(v) information dissemination (methods of providing infor-
mation about genetic services to patients and service 
providers).
The above factors reflect the three aspects of phase three (T3) 
of translation research in genomic medicine [where “translation” 
is defined as “the sequence of events in which a proven scientific 
discovery is successfully integrated into established practice and 
policy” (9)], namely integrating interventions into existing pro-
grams and structures (implementation research), promoting the 
adoption of the interventions by stakeholders (diffusion research), 
and increasing the spread of knowledge about evidence-based 
interventions (dissemination research).
The present project will, therefore, take all these factors related 
to genetic services into account in order to identify, classify, and 
evaluate genetic service delivery models for predictive genetic 
testing present in European countries and in selected extra-
European (Anglophone) countries.
by comparing sets of process and outcome measures. In this way, the study will provide 
a basis for future recommendations to decision makers involved in the financing, delivery, 
and consumption of genetic services.
Keywords: genetic services, genetic delivery models, genetic testing, systematic review, expert interviews
FIGUrE 1 | The 10 questions of the USA Genetic Service Policy Project Report (8).
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MAtErIAls AND EQUIPMENt
The project will be carried out through a multidimensional 
approach, which includes (i) a preliminary (non-systematic) 
literature search to define genetic services and genetic delivery 
models; (ii) a systematic review of published literature on existing 
genetic service delivery models and selected country websites for 
policy documents; (iii) structured interviews with health experts 
on genetic service delivery models, policies governing the use 
of genomics medicine, and evaluation of genetic testing and 
related services in their respective countries; and (iv) a survey of 
European Public Health Association (EUPHA) members’ knowl-




Although the terms “genetic(s) service(s)” and “genetic delivery 
models” appear frequently in the peer-reviewed literature and in 
documents on genetics policy-related websites, they are usually 
not defined. Therefore, a preliminary (non-systematic) literature 
search was carried out to define the two terms. A common 
search strategy was used to identify articles from three electronic 
databases (Pubmed, Google, and Google scholar) with the fol-
lowing keywords: genetic(s) service, medical genetics, genetic 
service delivery, genetic(s) service delivery model, and genomic 
service delivery. Only articles defining the two terms “genetic(s) 
service(s)” and “genetic delivery models,” describing or classify-
ing genetic service delivery models and published in English or 
Italian languages were included. No period restrictions were 
applied.
Systematic Review of the Literature
The systematic review focusing on existing genetic service 
delivery models will be performed according to the PRISMA 
Statement (10). The search will be conducted using five medical 
electronic databases (PubMed, Scopus, ISI Web of Knowledge, 
Google, and Google Scholar) with the following search term: 
genetic(s) services OR genetic(s) service provision OR genetic(s) 
service delivery OR genomic service delivery OR genetic(s) 
delivery models. The inclusion criteria will be:
– relevant articles and reports on pilot studies, best practices, 
and funded projects inherent to genetic service delivery;
– genetic services concerning the delivery of all types of genetic 
tests;
– genetic services for predictive genetic testing provided by 
genetic specialist teams, and healthcare professionals practic-
ing in primary or secondary care;
– publication year between 2000 and 2015;
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– studies published in English and Italian languages;
– interventions carried out in European and extra-European 
countries (the USA, Canada, Australia, and New Zealand).
The present project will focus on genetic service delivery 
models in Europe; therefore, other geographical areas considered 
will be used only for comparison.
The exclusion criteria will be:
– studies reporting only on genetic counseling services;
– descriptive studies where a specific delivery model cannot be 
identified;
– studies not specifying the type of genetic test offered.
Specific websites on PHG of EU countries (Table S1 in 
Supplementary Material) and extra-European countries (Table 
S2 in Supplementary Material) will be consulted as an additio-
nal resource to identify policy documents on delivery models 
(e.g., guidelines, protocols, position statements).
Experts’ Interviews on Genetic Service Delivery 
Models
Experts’ interviews will be conducted through an online ques-
tionnaire to:
(a) identify any genetic services delivery model that was not 
identified through the literature search;
(b) enhance the collection of process and outcome indicators 
used for quality assessment of genetic services delivery 
models;
(c) collect opinions of expert panels on the genetic services 
delivery models in their countries, in terms of strengths and 
weaknesses—that are also barriers and facilitating factors for 
the genetic model implementation—and possible improve-
ments of the models.
Prior to the survey, a National Reference Group (NRG) will 
be established in each EU member state to select experts with 
different backgrounds and supervise the study at the national 
level. The panel of experts will have the following characteristics: 
(a) good knowledge or practical experience of at least one of the 
four types of selected genetic tests and (b) representative of each 
included country (e.g., in terms of regional or local autonomy in 
planning and delivery of health services, number, type, or geo-
graphic distribution of healthcare workforce in each country). 
The final number of experts will depend on the different contexts 
of each country.
The first part of the survey will focus on four types of genetic 
test (BRCA 1/2, Lynch syndrome, familial thrombophilia, and 
familial hypercholesterolemia). This part of the survey addresses 
healthcare professionals (e.g., medical geneticists, other medical 
specialists, and genetic counselors) working in genetic services 
with manager roles or in direct contact with patients requiring 
one of the four genetic tests. The NRG will select at least five 
experts for each genetic test to reach a minimum of 20 experts in 
each country. Stand-alone questionnaires are being developed for 
each genetic test with the following sections:
A. Demographic and professional information;
B. Genetic services delivery models for BRCA1/2, Lynch syn-
drome, familial thrombophilia, and familial hypercholester-
olemia genetic testing.
The second part of the survey addresses health information 
management professionals who deal with health data collection 
and analysis at local (health facilities), regional (regional agen-
cies), or national level (national institutes). The aim is to describe 
the flow and management of health information from each health 
facility to regional and national agencies where aggregate data are 
produced and used for planning activities. The NRG will select a 
minimum of five experts in each country. The related question-
naire will be composed of six sections:
A. Demographic and professional information;
B. Evaluation of genetic services activity;
C. Evaluation of quality of genetic services;
D. Evaluation of health outcomes;
E. Electronic records and genetic information;
F.  Coverage of genetic services in the country.
The third part of the survey addresses experts in policy 
planning and policy research of genetic services employed in 
national institutes (e.g., National Health Institutes, ministries), 
universities or clinical research centers and it will focus on policy 
of genetic testing and related services. The NRG will select at least 
five experts in each European country. The questionnaire will be 
composed of the following sections:
A. Demographic and professional information;
B. Policy issues;
C. Genetic services: access and availability;
D. Professional education and training.
Once the selection process is completed, a link to the final 
version of the online questionnaire will be e-mailed to the partici-
pants. They will be given a time frame of 6 months to participate 
in the survey. Up to two reminder e-mails will be sent to non-
responders 3 and 5 months after the initial e-mail to increase the 
response rate.
Knowledge and Attitudes of PH Professionals 
Regarding the Delivery of Genetic Services
Public health professionals may play different roles in the 
translation of genome-based knowledge and technologies into 
PH. They may use genomics tools to evaluate the health impact 
of PH interventions on different subsets of the population (1). 
Despite the fact that several surveys have been performed to 
evaluate knowledge, attitudes, and professional behaviors of 
physicians toward the integration of human genomic discoveries 
in clinical practice (11–16), only one study has been conducted 
for PH professionals. The study focused on knowledge, attitudes, 
and training needs of the members of the Italian Society of 
Hygiene, Preventive Medicine, and Public Health (S.It.I.) in the 
field of predictive genetic testing for chronic diseases (17). The 
study highlighted that Italian PH professionals have the required 
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attitudinal background to contribute to the proper use of pre-
dictive genetic testing for chronic diseases, but need additional 
training to increase their methodological skills.
Looking ahead to the incorporation of PHG into PH prac-
tice in Europe, a similar survey will be conducted in a sample 
of European PH professionals, members of EUPHA. EUPHA 
is the umbrella organization for PH associations and institutes 
in Europe. It is composed of 71 member organizations from 41 
countries and has about 5.900 individual members. The online 
survey will be carried out in order to obtain a picture of the 
European PH community readiness to incorporate PHG in their 
practice. The survey will focus on attitudes and knowledge of PH 
professionals toward genomic applications in clinical practice, the 
delivery of genetic services, evaluation of genetic service delivery 
models, and the role of PH professionals in the implementation 




C. Knowledge of genetic testing and delivery of genetic services;
D. Attitudes on genetic testing and the delivery of genetic 
services;
E. Attitudes regarding the roles of PH professionals in PHG.
A link to the final version of the online questionnaire will be 
e-mailed to the 5.900 EUPHA members. The individual members 
could fit one of the following categories: (a) PH professionals 
involved in PHG; (b) PH professionals not involved in PHG; 
(c) not PH professionals involved in PHG (e.g., geneticists); 
(d) not PH professionals not involved in PHG (e.g., infectious 
diseases specialists). A filter question will direct professionals not 
involved in PHG activities to a reduced version of the question-
naire, comprised of only four items in sections C and D.
Participants will be given a time frame of 6 months to par-
ticipate in the survey. To increase the response rate, up to two 
reminder e-mails will be sent to non-responders 3 and 5 months 
after the initial e-mail. In case the response rate should not be 
sufficient, hard copies of the study will also be distributed to the 
participants during a EUPHA Conference. A pilot phase will 
be conducted prior to administration of the questionnaire to 
EUPHA members in order to ensure practicability, validity, and 
correct interpretation of results.
Data Management
Data from the literature review and surveys will be collected and 
analyzed by the authors. A data extraction form has been devel-
oped specifically to collect relevant information from the studies 
included in the systematic review (Table S3 in Supplementary 
Material) and is composed of three parts:
–  General description of the study and the genetic service. 
This section collects general information about the study 
(i.e., authors, title of the study, etc.) and the genetic service 
(i.e., practice setting, financing mechanism, etc.);
–  Information on patients and pathways to care. This section 
investigates the characteristics of the target population of 
the genetic service and pathways to care, as well as cost- 
effectiveness and efficacy of the genetic service;
–  Genetic service evaluation. This section investigates the type 
of genetic service delivery model, strengths, and weaknesses 
of the model, as well as the genetic service capacity in terms 
of population and geographic area served, staff qualification, 
laboratory characteristics, and outcome evaluation.
Five members of the working group made an independent 
evaluation of each genetic service using the data extraction form, 
followed by extensive group discussions. Eventual discrepancies 
were resolved after discussion with the coordinators of the project. 
The coordinators were responsible for revising and standardizing 
the preliminary results and for supporting the working group 
throughout the whole evaluation process.
In the experts’ interview, the diffusion of each genetic service 
delivery model in each country will be assessed through a three-
point Likert scale (“poorly diffused,” “sufficiently diffused,” “highly 
diffused”), while the likelihood that a specific genetic services 
pathway is associated with one of the identified delivery models 
will be assessed by another three-point Likert scale (“unlikely,” 
“likely,” “very likely”).
In the EUPHA survey, attitudes of PH professionals will be 
assessed through a three-point Likert scale (“agree,” “uncertain,” 
and “disagree”), while knowledge will be assessed through a 
combination of multiple choice questions and three-point Likert 
scale answers.
Internal consistency of all questionnaires will be assessed by 
obtaining Cronbach’s alpha coefficients.
The final results of the project will be available in 2019 and 
will be disseminated through the EUPHA network, the Italian 
Network for Genomics in Public Health (GENISAP), seminars 
and workshops. In particular, internal workshops and open 
seminars have been scheduled for the period 2016–2018.
ANtIcIPAtED rEsUlts
The preliminary literature search produced eight records useful 
in defining the terms “genetic(s) service(s)” and “genetic delivery 
models” and in identifying the wide range of genetic services 
provision (8, 18–25). The definitions of genetic services were 
provided by the GSPP (8) (“genetic testing, diagnosis of genetic 
conditions, genetic counseling, and treatments for individuals 
with or at risk of genetic disorders”) and the article by Silvey et al. 
(18) (“medical genetic services are provided by specialist genetic 
centers and they include activities such as diagnostic laboratory 
services, education of healthcare professionals, participation in 
research, and expert advice to policy makers”). The two defini-
tions of genetic services are comprised in the Italian “Guidelines 
for Medical Genetics Activities” (19) in which genetic services are 
defined as specialized services offered to individuals and families 
with genetic conditions or at risk of developing or transmitting a 
genetic condition. The guidelines also state that genetics services 
comprise clinical genetics (genetic counseling, diagnosis, treat-
ment, and follow-up) and genetic laboratory services (genetic 
testing). Genetics services collaborate in education and train-
ing of healthcare professionals and provide information to the 
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public. The definition of genetic services reported by the Italian 
“Guidelines for Medical Genetics Activities” has been adopted by 
the working group of the present project.
Particularly useful in defining the term “genetic delivery 
models” were the 10 questions of the GSPP Report (8), which 
summarize the main aspects inherent to the delivery of genetic 
services (Figure  1). For the purpose of the present project, a 
genetic service delivery model for the provision of predictive 
genetic testing is defined as the broad context within the PHG 
framework in which genetic services are offered to individuals and 
families with or at risk of genetic disorders. In other words, a genetic 
delivery model is a combination of personal healthcare services 
provided by healthcare professionals to individuals and families 
(i.e., diagnosis, treatment/management, and information) and 
PH services and functions (i.e., population screening, financing, 
policy development, workforce education, information/citizen 
empowerment, service evaluation, and research).
The two articles by Gu et al. (22, 23) and the review by Battista 
et al. (25) provided a classification of genetic service delivery mod-
els. Battista et  al. (25) classified genetic service delivery models 
into four types:
(i) multidisciplinary specialist clinics and coordinated ser-
vices in rare genetic disorders led by geneticists;
(ii) genetic services integrated in other medical specialties 
(e.g., oncogenetics, neurogenetics, cardiogenetics);
(iii) genetic services integrated into primary care;
(iv) genetic services provided in screening programs (e.g., pre-
natal and newborn screening).
The classification by Battista et al. (25) centers on the role of 
the healthcare professional involved in the provision of genetic 
services in each model (i.e., making referrals to genetic services 
for genetic counseling and/or genetic testing, direct request of 
a genetic test, interpretation of results, etc.). The article states 
that genetic services were provided mainly by geneticists, but 
in recent years more specialists are involved in genetic service 
provision alone or in collaboration with geneticists (e.g., primary 
care physicians/other specialists can carry out risk assessment, 
counseling and request genetic testing and interpret the results or 
refer patients to genetic services after risk assessment).
The classification provided by Gu et al. (22, 23) instead focuses 
mainly on the patients’ pathway from the point of access to the 
genetic service to diagnosis and treatment of the genetic disorder. 
The articles describe patients’ pathways prior to and after genetic 
testing, and include the commercial model where a genetic test 
can be ordered directly by an individual without involving health-
care professionals:
(i) The Patient–Doctor–Counselor Model;
(ii) The Patient–Doctor–Lab Model;
(iii) The Patient–Counselor–Lab Model; and
(iv) The Patient–Lab (Commercial) Model (i.e., direct-to-
consumer genetic testing).
The final classification of genetic services delivery models will 
take into consideration the delivery models described by Battista 
et al. (25) and all possible patients’ pathways described by Gu et al. 
(22, 23) or identified through the systematic review of the litera-
ture. Each genetic service provision identified will be described 
and compared between European countries and in selected 
extra-European countries through a set of factors that have been 
summarized by the USA Report (GSPP; see Figure 1) (8).
The process and outcome indicators collected from the present 
project will be used to define a minimum set of indicators neces-
sary for the assessment of genetic services through a consensus 
procedure among the partners of the PRECeDI project (Italy, UK, 
Hungary, Spain, the Netherlands, Canada, and the USA).
With regard to knowledge and attitudes of PH professional, 
we can anticipate that poor knowledge of genetics will be a bar-
rier to the provision of genetic services (e.g., risk assessment, 
counseling, interpretation of genetic test results, and so on). 
It will surely interfere with the process of incorporating genetics 
into clinical practice.
Results of this project may be disseminated in scholarly arti-
cles and at academic conferences but no personal information 
about the participants will be used in the reports or manuscripts.
DIscUssIoN
The transfer of genomic technologies from research to clinical 
application is influenced not only by several factors inherent 
to research goals and delivery of healthcare but also by exter-
nal and commercial interests that may cause the premature 
introduction of genetic tests in the public or private sector (i.e., 
introduction of a test despite insufficient evidence regarding its 
analytical validity, clinical validity, and utility). Furthermore, 
current genetic services are delivered without a standardized 
set of process and outcome measures, which are essential 
for the evaluation of healthcare services. It is important that 
only genetic/genomic applications with proven efficacy and 
effectiveness are delivered to populations, and particularly that 
technologies have favorable cost-effectiveness ratios (21). This 
study will facilitate the identification of appropriate models 
for the provision of predictive genetic testing in the European 
context by identifying, classifying, and subsequently compar-
ing outcome and process measures of genetic service delivery 
models. Such classification and consideration of process and 
outcome indicators will facilitate the comparison of models 
across different countries and health systems. The EUPHA 
survey will be useful to describe and compare current points 
of views, information, and educational needs of PH profession-
als in Europe. Health professionals’ knowledge and attitudes 
regarding the delivery of genetic services is an indicator of the 
European PH community’s preparedness to incorporate PHG 
into their practice. Hence, this indicator could be a barrier or 
a facilitating factor for the implementation and provision of 
genetic services in Europe.
In conclusion, the current project will identify possible points 
of improvement for currently implemented genetic services deliv-
ery models in Europe and provide recommendations to decision 
makers involved in the financing, delivery, and consumption of 
genetic services.
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